In this study, we did not restrict either the GLP-1 treatment cohort or the control cohort to any specific medication regimen, dosage trajectory or adjunctive interventions, as the intent was to capture the full range of possible real-world medication usage that is occurring
Sphingosine 1-phosphate metabolism and insulin signaling
Retatrutide activates three receptors (GLP-1, GIP, and glucagon), while Zepbound activates two (GLP-1 and GIP)
This increases duration of receptor interaction and sustains anabolic signaling over a longer period
Subsequent research has shown that CJC-1295 may enhance sleep, increase muscle mass, and stimulate fat loss in test subjects [1]
Based on patient comfort, the medication can be administered by self-injection at home, or by administration in office from one of our healthcare professionals